A DES drug lawsuit is a product-liability claim brought by someone exposed to diethylstilbestrol — a synthetic estrogen prescribed to pregnant women from the 1940s through 1971 — or by their children, seeking damages from the manufacturers for cancers, reproductive injuries, and other health harms linked to that exposure. These cases reshaped American tort law because of one hard problem: the drug was made by dozens of companies from an identical formula, and by the time injuries appeared decades later, most plaintiffs could not say whose pills their mother took. Courts answered with new liability rules that still define the litigation today.
What DES Is and Why People Sue
Diethylstilbestrol was first synthesized in 1938 and never patented, so any manufacturer could produce it. The FDA approved it for miscarriage prevention on July 1, 1947, and as many as 287 companies ultimately made DES or related compounds from a generic, government-established formula.1ScienceDirect. Diethylstilbestrol Revisited2National Cancer Institute. DES Fact Sheet3National Cancer Institute, DCEG. DES Follow-Up Study
The injuries that drive DES lawsuits fall into several categories. Clear cell adenocarcinoma affects roughly 1 in 1,000 DES daughters, with cases documented in patients as old as 55.4DES Action USA. DES Daughters5DES Action USA. DES and Cancer6DES Action USA. DES Sons7PMC. DES Exposure and Male Health Effects
Who Can Sue
The most common plaintiffs are DES daughters diagnosed with cancer or serious reproductive injuries, followed by DES sons. Mothers who took the drug can also sue in their own right. Third-generation plaintiffs — the grandchildren of women who took DES — face a much steeper path in U.S. courts.
The leading decision on grandchildren’s claims is Enright v. Eli Lilly and Co., decided by the New York Court of Appeals in 1991. Karen Enright, an infant plaintiff, alleged that her disabilities stemmed from a premature birth caused by her mother’s own in utero DES exposure. The court ruled that DES manufacturers are not liable to third-generation plaintiffs, reasoning that recognizing such claims would push tort concepts “beyond manageable bounds” and risk “overdeterrence” that could discourage pharmaceutical research or push beneficial drugs off the market.8Cornell Law Institute. Enright v. Eli Lilly and Co.9vLex. Enright by Enright v. Eli Lilly and Co. The ruling left the mother’s own claims untouched but effectively closed the door on third-generation suits in New York. Legal scholars have continued to argue for preconception tort liability.10PubMed. Third-Generation DES Litigation3National Cancer Institute, DCEG. DES Follow-Up Study7PMC. DES Exposure and Male Health Effects
The Identification Problem and Market-Share Liability
Because hundreds of companies made chemically identical DES and injuries surfaced decades later, most plaintiffs could not identify which manufacturer made their mother’s pills. Medical records were lost. Prescribing doctors had died or retired. Many early cases were dismissed on that ground alone.11US Pharmacist. DES Returns to the Courtroom By February 1991, more than 1,000 DES lawsuits were pending nationwide, and identification remained the central obstacle.12National Center for Biotechnology Information. DES Litigation Overview
The breakthrough came in 1980 with Sindell v. Abbott Laboratories. The California Supreme Court created market-share liability: a plaintiff could sue manufacturers that collectively held a substantial share of the DES market, and the burden shifted to each defendant to prove it could not have made the specific pills. A manufacturer that could not make that showing would be liable in proportion to its market share. The court reasoned that because DES was fungible and identification had been made impossible by time, manufacturers in a position to spread the cost through insurance should bear it rather than the innocent plaintiff.13Justia. Sindell v. Abbott Laboratories14Stanford. Sindell v. Abbott Laboratories
New York adopted its own version in Hymowitz v. Eli Lilly and Co. (1989), using a national market share rather than a local one. Nearly 500 DES cases were pending in New York at the time. Hymowitz also upheld the constitutionality of a 1986 New York statute that revived, for a one-year window, DES personal injury claims that had already expired under the statute of limitations.15vLex. Hymowitz v. Eli Lilly and Co. Not every state has adopted market-share liability, so whether this theory is available depends on the state where the case is filed.
Statute of Limitations and the Discovery Rule
Because DES injuries emerge years or decades after exposure, deadlines are a recurring hurdle. Most states apply some form of the discovery rule: the clock does not start until the plaintiff discovers, or reasonably should have discovered, both the injury and its connection to DES.16Cambridge University Press. Statutes of Limitations: The Special Problem of DES Suits Many states also toll the limitations period for minors until the age of majority.
Courts have divided over what counts as the triggering injury. Some have asked whether a minor condition such as adenosis starts the clock, or whether it only begins when a serious disease like adenocarcinoma is diagnosed.16Cambridge University Press. Statutes of Limitations: The Special Problem of DES Suits New York addressed the problem legislatively with the 1986 revival statute upheld in Hymowitz.
Notable Case Outcomes
One of the earliest trials to reach a verdict was Bichler v. Eli Lilly and Co., filed in New York and tried in May 1979. The plaintiff, a young woman who developed cervical and vaginal cancer at 17 after prenatal exposure, could not prove Eli Lilly had made her mother’s pills. The jury agreed on that point, but the case proceeded on a concerted-action theory — that Lilly and other manufacturers had acted in concert in testing and marketing DES. A jury found Eli Lilly liable and awarded $500,000. The New York Court of Appeals affirmed in 1982, and the appellate finding that Lilly had been negligent in testing DES was later given collateral estoppel effect in subsequent New York cases.17vLex. Bichler v. Eli Lilly and Co.18Justia. Collateral Estoppel in DES Cases
A separate line of cases grew out of the Dieckmann Study at the University of Chicago’s Lying-In Hospital in 1951 and 1952, where nearly 1,100 pregnant women were randomized to receive DES or a placebo without being told they were in a study or what they were taking. In 1978, former U.S. Representative Patsy T. Mink of Hawaii, who had been a participant, and other women sued, seeking $77.7 million. In Mink v. University of Chicago, the court dismissed strict liability and failure-to-warn claims because Illinois law required physical injury to the plaintiffs themselves, but upheld a battery claim on the theory that nonemergency medical experimentation without consent is unauthorized contact. The case settled for $225,000, and the university agreed to provide free medical exams and cancer treatment for the exposed offspring. A separate suit, Wetherill v. University of Chicago (1983), settled out of court for an undisclosed amount.19The Washington Post. University, Firm Sued Over DES Tests in Mothers12National Center for Biotechnology Information. DES Litigation Overview
A more recent high-profile case went to trial in January 2013, when four sisters from Tresckow, Pennsylvania — Francine Melnick, Andrea Andrews, Donna McNeely, and Michele Fecho — sued Eli Lilly in federal court in Boston. Each had been diagnosed with breast cancer between 1997 and 2003, and they alleged prenatal DES exposure. Eli Lilly argued that no evidence linked DES to breast cancer in daughters, that the mother’s medical records were unavailable, that the prescribing doctor was dead, and that the mother had not met the company’s criteria for a DES prescription at the time.20CBS News Boston. Drug Maker Settles With Sisters Who Blame Cancer on Pregnancy Drug21WBUR. Pregnancy Drug Cancer Settlement22WGBH. Eli Lilly Settles Out of Court
DES Litigation Outside the United States
DES was sold in France primarily as Distilbène by UCB Pharma, which held an estimated 97% of the market, with Borne-Novartis holding the remainder.23Cairn.info. Distilbène and French Science Policy In 2002, the Tribunal of Nanterre ruled for two DES daughters against UCB Pharma and awarded 15,244 euros, a ruling confirmed on appeal in 2004.24Diethylstilbestrol.co.uk. Distilbene Lawsuits The major shift came on September 24, 2009, when the Cour de Cassation partially reversed the burden of proof: once experts confirm in utero DES exposure and a causal link to a disease, the manufacturer must prove its product was not responsible. Where it is impossible to tell whether the exposure was to Distilbène or Stilbestrol-Borne, French courts have held both companies jointly liable in proportion to market share. A 2011 appellate decision awarded roughly €1.7 million to a third-generation victim, holding UCB Pharma responsible for complications in a DES grandchild — a different outcome than the U.S. rule in Enright.25DES France. Décisions de Justice Even so, only a few hundred of an estimated 160,000 exposed individuals in France have gone through legal proceedings, and cases often take a decade or more.
In the Netherlands, where DES was banned for use during pregnancy in 1976, six DES daughters sued ten pharmaceutical companies in 1986. The Dutch Supreme Court’s 1992 ruling rejected market-share liability and applied joint and several liability instead, holding manufacturers responsible unless they could prove their product did not cause the harm. Rather than litigate case by case, pharmaceutical companies and their insurers established the DESFonds, capitalized at €35 million, which began payments in 2007. The fund covers the range of DES-related disorders, with compensation scaled to disease severity and strength of causation. When an Amsterdam court validated the arrangement, more than 100,000 people were potentially eligible and only four filed objections.26Poelman CS. The Tragedy of the DES Daughters27The Lancet. Dutch DES Fund Collective Settlement
Federal Preemption and the Right to Sue
Drug manufacturers have long argued that FDA approval of a label preempts state-law failure-to-warn claims. The Supreme Court addressed that argument in Wyeth v. Levine (2009). The case involved a different drug, but the holding applies to pharmaceutical liability suits generally. By a 6–3 vote, the Court held that federal law does not preempt state tort claims against drugmakers for inadequate warnings, calling FDA labeling requirements a “floor, not a ceiling” and placing primary responsibility for a drug’s label on its manufacturer.28Justia. Wyeth v. Levine29Cornell Law Institute. Wyeth v. Levine Plaintiffs retain the right to sue under state law even where the FDA previously approved the labeling.
Where to Get Help
DES Action USA, founded in 1978 and operating as an all-volunteer nonprofit under the MedShadow Foundation since 2015, is the only national organization dedicated to DES-exposed individuals and their families. It provides free medical information, maintains a list of DES-aware doctors, runs the Clear Cell Adenocarcinoma Registry, and offers attorney referrals for those considering legal action. It accepts no pharmaceutical industry funding.30DES Action USA. About Us31DES Action USA. DES Action USA